In a randomized phase II trial, the erlotinib and bevacizumab combination significantly prolonged progression‐free survival compared to erlotinib alone in patients with lung cancers harboring EGFR mutations (Seto et al., 2014). The gene discussed is EGFR; the disease is lung carcinoma.